BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), foto del prodotto

Referto di laboratorio

PDF
Testato
Testato
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratorio
Analiza Białek
Data
October 2026
Risultato
20.34 mg per tablet (20 mg label)
N. ordine
Password

Testato in modo indipendente, verificabile con la password direttamente presso il laboratorio.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

In sintesi

Tamoxifen (Nolvadex) in cifre

I dati chiave dalla nostra enciclopedia.

Voce completa dell'enciclopedia
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Conoscenze

Tutto su Tamoxifen (Nolvadex)

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Confronti

Come si confronta

Correlati

Prodotti correlati